Results 201 to 210 of about 29,341 (237)
Some of the next articles are maybe not open access.
Clusterin regulates transthyretin amyloidosis
Biochemical and Biophysical Research Communications, 2009Transthyretin (TTR) is a human disease-associated amyloidogenic protein that has been implicated in senile systemic amyloidosis (SSA) and familial amyloidotic polyneuropathy (FAP). FAP typically results in severe and early-onset disease, and the only therapy established so far is liver transplantation; thus, developing new strategies for treating FAP ...
Ko-Woon, Lee +9 more
openaire +2 more sources
Transthyretin familial amyloid polyneuropathy
2013TTR FAP is characterized by phenotypic and genotypic heterogeneity. The severity of polyneuropathy along with autonomic dysfunction and heart involvement makes it a life-threatening disease. This protein is mainly produced by the liver. Molecular genetic testing is essential in the diagnostic strategy.
V, Planté-Bordeneuve, P, Kerschen
openaire +2 more sources
Transthyretin amyloid cardiomyopathy
The American Journal of the Medical Sciences, 2023Giuseppe, Famularo, Guido, Ventroni
openaire +2 more sources
Hereditary transthyretin-related amyloidosis
Acta Neurologica Scandinavica, 2018Hereditary transthyretin(TTR)-related amyloidosis (ATTRm amyloidosis) is an endemic/non-endemic, autosomal-dominant, early- and late-onset, rare, progressive disorder, predominantly manifesting as length-dependent, small fiber dominant, axonal polyneuropathy and frequently associated with cardiac disorders and other multisystem diseases.
Josef Finsterer +5 more
openaire +2 more sources
Monoclonal antibodies to transthyretin
Scandinavian Journal of Clinical and Laboratory Investigation, 1986Monoclonal antibodies (mabs) have been raised against human transthyretin (hTTR). The protein was isolated by an affinity chromatography procedure using Sepharose-hRBP and BALB/c mice were immunized. Following fusion with SP 2/0 myeloma cells, 26 single cell clones producing antibodies against hTTR were isolated.
V P, Collins +3 more
openaire +2 more sources
Transthyretin familial amyloid polyneuropathy
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2018Transthyretin family amyloid polyneuropathy (TTR-FAP) is a progressive, ultimately fatal disease. It manifests itself primarily with sensory, motor and autonomic polyneuropathy and/or cardiomyopathy and is caused by extracellular deposition of insoluble amyloid fibrils in the endoneurium.
openaire +2 more sources
Pathogenesis of transthyretin amyloidosis
Amyloid, 2012Current dogma for transthyretin (TTR) pathogenesis is that mutations in TTR alter its structure such that the tetramer becomes unstable and prone to release of monomer which then becomes the putative building block of the fibril. This hypothesis is supported by thermodynamic data showing decreased stability of mutant TTR tetrameric proteins and ...
openaire +2 more sources
Tafamidis for transthyretin amyloidosis
Drugs of Today, 2012Tafamidis meglumine (Vyndaqel®, Pfizer) is a novel, first-in-class drug for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare neurodegenerative disorder characterized by progressive sensory, motor and autonomic impairment that is ultimately fatal.
openaire +2 more sources
RNA-targeting and gene editing therapies for transthyretin amyloidosis
Nature Reviews Cardiology, 2022Alberto Aimo +2 more
exaly